Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 09, 2022 at 04:34 am
Share
Yung Zip Chemical Ind. Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 125.23 million compared to TWD 88.63 million a year ago. Net income was TWD 10.73 million compared to net loss of TWD 5.25 million a year ago. Basic earnings per share from continuing operations was TWD 0.25 compared to basic loss per share from continuing operations of TWD 0.12 a year ago. Diluted earnings per share from continuing operations was TWD 0.25 compared to diluted loss per share from continuing operations of TWD 0.12 a year ago.
For the nine months, sales was TWD 388.03 million compared to TWD 333.05 million a year ago. Net income was TWD 49.34 million compared to TWD 4.04 million a year ago. Basic earnings per share from continuing operations was TWD 1.16 compared to TWD 0.1 a year ago. Diluted earnings per share from continuing operations was TWD 1.16 compared to TWD 0.1 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
YUNG ZIP CHEMICAL IND. CO., LTD. 
